GSK Buys Nuvalent for $10.6B to Add Two Lung Cancer Drugs
GSK is paying $10.6 billion to acquire Nuvalent, a biotech with two lead drugs aimed at non-small cell lung cancer (NSCLC), MedCity News reports. Both programs are under FDA review, and GSK says it plans to launch them this year if they win approval.
The two drugs target different driver mutations in NSCLC, the most common form of lung cancer. Precision oncology agents like these treat tumors defined by specific genetic alterations rather than by where the cancer originates, a strategy that has reshaped how late-stage lung cancer is managed. Nuvalent designed its candidates to overcome resistance and reach the brain, common weaknesses of earlier targeted therapies.
The deal continues a wave of large pharma buying late-stage oncology assets to refill pipelines ahead of looming patent expirations. For GSK, acquiring near-commercial drugs shortens the path to revenue and deepens its bet on targeted cancer treatment, a market where rivals including AstraZeneca and Pfizer are aggressively competing.
Sources